CLRB

Updated CLOVER WaM Phase 2b analyses show durable responses in heavily pretreated patients and suggest greater benefit when used earlier in treatment paradigm Company to present Phase 3 trial-in-progress design as site activation advances, first patient dosing remains on track for 1Q 2027 and FDA filing for accelerated approval remains targeted for 1H27 FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of cancer therapies, today announced that three posters highlighting compelling data and clinical progress for its lead radiopharmaceutical candidate, iopofosine I 131 in Waldenström macroglobulinemia (WM), will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 12 – 15 in New Orleans, Louisiana.

FLORHAM PARK, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company will report financial results for the third quarter ended September 30, 2026, and provide a corporate update on November 10, 2026, at 8:30 a.m.

Durable Complete Response Achieved with Single Administration of Iopofosine I 131  Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential Utility Across a Range of B-cell Malignancies FLORHAM PARK, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today reported results from a case study highlighting a durable complete response in a heavily pretreated patient with diffuse large B-cell lymphoma (DLBCL) treated with iopofosine I 131.

Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months

Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy

Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript

Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program

FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2026, and provide a corporate update on August 13, 2026, at 8:30 a.m.

Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in  Relapsed/Refractory Multiple Myeloma

Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in  Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy